Key Highlights

  • SANUWAVE Health, Inc. (NASDAQ:SNWV) changed hands at USD 2.84, a drop of 50.44% in trading on November 5, 2026, per published market data, on light Volume of roughly 214,000 shares.
  • Second quarter 2026 Revenue came to USD 9.7 million, falling 3% from USD 10.1 million, and gross Margin eased to 76.2% from 78.1% a year earlier.
  • On August 6, 2026, the company pulled its 2026 guidance, a previous USD 51 million to USD 55 million revenue view, and said it would wait for the definitive CMS regulation due in the fourth quarter.
  • First quarter 2026 revenue had grown 3.1% to USD 9.6 million, and revenue over the last four quarters totaled roughly USD 44 million, according to published market figures.

Forecast Pulled Before a Medicare Ruling

SANUWAVE Health, Inc. (NASDAQ:SNWV) last made a major update on August 6, 2026, when it posted second quarter results and suspended its 2026 forecast, stating it would reassess after the CMS final rule, due in the fourth quarter of 2026. Revenue was USD 9.7 million, off 3% year over year, and gross margin dropped to 76.2% from 78.1%. A preliminary estimate issued July 13, 2026 had revenue of USD 9.6 million to USD 9.8 million, above an earlier June estimate, later amended to USD 8.5 million to USD 9.5 million. The stock then fell 50.44% in trading on November 5, 2026.

Management's View of the Business

During the second quarter conference call, executives described record applicator sales alongside a steep decline in system sales, pointing to the saturated secondhand device market and turbulence from cuts to Medicare reimbursement. The company release referenced reimbursement developments and a 2027 CMS proposed rule for code 97610. Applicators are consumables and typically generate steadier income than Capital systems, so a mix shift can prop up recurring sales while weighing on headline growth. Published market figures show trailing revenue of roughly USD 44 million, and published per-share Earnings figures are excluded because they do not match reported operating numbers. With guidance still withdrawn, the company has not quantified forward revenue, which broadens the spread of possible results investors have to weigh.

Light Trading, Reversal Risk and Upcoming Dates

With the share price below USD 3 and a Market Value of about USD 40 million to USD 50 million, a limited number of trades can move the price, spreads may be wide and the move may snap back, so the slide is better treated as noise than as a settled trend. Principal risks include the forthcoming CMS ruling, falling system sales, margin pressure and funding needs if growth stalls. Third quarter results appear on published calendars for around November 6, 2026, a date the company has not confirmed here. Watchers will focus on the fourth quarter CMS result and any restored forecast.

Where Things Stand

SANUWAVE Health, Inc. (NASDAQ:SNWV) lost roughly half its quoted value because the shares are small, thinly traded and exposed to an unresolved Medicare reimbursement decision, after pulling guidance back in August. Weaker system sales and a narrower gross margin left holders with little fundamental padding. The quoted move is intraday and may fade. The next markers are third quarter results, which published calendars put near November 6, 2026, and the CMS decision slated for the fourth quarter of 2026.